ClinicalTrials.Veeva

Find clinical trials for Eczema in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Dyssomnias
Parasomnias
Food Hypersensitivity
Hypersensitivity
Psoriasis

Eczema trials near Toronto, ON, CAN:

Locations recently updated

A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy (ADHAND)

The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. Th...

Enrolling
Atopic Hand Eczema
Atopic Dermatitis
Drug: Tralokinumab
Drug: Placebo

Phase 3

LEO Pharma
LEO Pharma

Toronto, Ontario, Canada and 53 other locations

This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 52 weeks by subjects with atopic dermatitis (eczema)....

Active, not recruiting
Atopic Dermatitis Eczema
Drug: ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%

Phase 3

Arcutis Biotherapeutics
Arcutis Biotherapeutics

Toronto, Ontario, Canada and 91 other locations

the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo.OpSCF or placebo will be adm...

Active, not recruiting
Atopic Dermatitis
Biological: OpSCF
Biological: Placebo

Phase 2

Opsidio

Oshawa, Ontario, Canada and 21 other locations

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

Phase 3

AbbVie
AbbVie

Markham, Ontario, Canada and 179 other locations

Locations recently updated

This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).

Enrolling
Atopic Dermatitis Eczema
Drug: ANB032
Drug: Placebo

Phase 2

AnaptysBio
AnaptysBio

Etobicoke, Ontario, Canada and 77 other locations

The purpose of this study is to evaluate the long-term safety and tolerability of ruxolitinib cream in adolescents with Atopic Dermatitis (AD).

Active, not recruiting
Atopic Dermatitis (AD)
Drug: Ruxolitinib Cream

Phase 3

Incyte
Incyte

Toronto, Ontario, Canada and 37 other locations

The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...

Active, not recruiting
Atopic Dermatitis
Drug: Dupilumab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Markham, Ontario, Canada and 83 other locations

The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moder...

Enrolling
Eczema
Atopic Dermatitis
Drug: Lebrikizumab
Drug: Placebo

Phase 3

Lilly
Lilly

Mississauga, Ontario, Canada and 94 other locations

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to <18...

Enrolling
Eczema
Atopic Dermatitis
Drug: Topical corticosteroid
Drug: Placebo

Phase 3

Lilly
Lilly

Mississauga, Ontario, Canada and 96 other locations

This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or a...

Enrolling
Atopic Dermatitis
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

Phase 3

Incyte
Incyte

Peterborough, Ontario, Canada and 105 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems